AI assistant
Sending…
SELLAS Life Sciences Group, Inc. — Director's Dealing 2018
Apr 24, 2018
33651_dirs_2018-04-24_3038efc8-6509-4bf2-b162-02f728354151.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SELLAS Life Sciences Group, Inc. (SLS)
CIK: 0001390478
Period of Report: 2018-04-20
Reporting Person: Mack Gene (CFO and Treasurer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-04-20 | Stock Option (Right to Buy) | $5.38 | A | 40000 | Acquired | 2028-04-19 | Common Stock (40000) | Direct |
Footnotes
F1: One-quarter (1/4) of the option shares will vest and became exercisable one year from the April 20, 2018 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
More from SELLAS Life Sciences Group, Inc.
Regulatory Filings
2026
May 12
Interim / Quarterly Report
2026
May 12
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Mar 20
Major Shareholding Notification
2026
Jan 30
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9